Docoh
Loading...

ALVR AlloVir

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Thursday
20 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Thursday's morning trading, 152 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
19 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's morning trading, 400 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
18 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday morning saw 454 companies set new 52-week lows.
Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $45
18 Jan 22
News, Price Target, Analyst Ratings
Morgan Stanley maintains AlloVir (NASDAQ:ALVR) with a Overweight and lowers the price target from $48 to $45.
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
Stocks Hitting New 52-Week Lows Today
3 Jan 22
News, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 60 companies achieved new lows for the year.
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
17 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $32
17 Dec 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $37 to $32.
AlloVir Saturday Announced Prelim. Data From Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study At American Society Of Hematology Meeting
13 Dec 21
Biotech, News, FDA, General
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, 11 remained free of
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
6 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector recorded weekly losses, reversing course from the previous week's advance.
SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $37
8 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $41 to $37.
AlloVir Q3 EPS $(0.72) Down From $(0.58) YoY
5 Nov 21
Earnings, News
AlloVir (NASDAQ:ALVR) reported quarterly losses of $(0.72) per share. This is a 24.14 percent decrease over losses of $(0.58) per share from the same period last year.

Press releases

From Benzinga Pro
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
5 Jan 22
Press Releases
Treatment of AdV infection is posoleucel's second potential indication to receive RMAT designation Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment Proof-of-concept study of
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
3 Jan 22
Press Releases
AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
16 Dec 21
Press Releases
AlloVir (NASDAQ:ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
11 Dec 21
Press Releases
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, 11 remained free of
AlloVir to Host Virtual Investor Event
2 Dec 21
Press Releases
AlloVir (NASDAQ:ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST. The event will feature an AlloVir corporate update
AlloVir Reports Third Quarter 2021 Financial Results
5 Nov 21
Press Releases
Company is prioritizing prevention and treatment programs with the potential to transform transplant patient care and outcomes Positive interim data from posoleucel multi-virus prevention Phase 2 study will be